Treating solid tumors with minimal side effects

through selective depletion of immune-system inhibitors

CytoLogic, Inc. is a Colorado-based early-stage medical device company focused on developing proprietary technology for treating cancerous tumors. The company’s UNLEASH® therapy, which involves selective filtration of blood plasma on a dialysis-type platform, is designed to increase a cancer patient’s natural immune response to malignant cells.

David Goffredo joins CytoLogic, Inc., as Advisor

by ctyoadmin on December 1, 2011

Boulder, Colorado, December 1, 2011 – CytoLogic, Inc., a Colorado-based medical device company, today...

BioPheresis and CytoLogic Close Settlement and License Agreements

by ctyoadmin on July 30, 2010

Heidelberg (Germany), July 30th, 2010 – BioPheresis Inc., Delaware, and its subsidiary BioPheresis...